KalVista Pharmaceuticals, Inc. (KALV) Issues Quarterly Earnings Results, Beats Estimates By $0.08 EPS
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) announced its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.08, Bloomberg Earnings reports. KalVista Pharmaceuticals had a negative net margin of 5,863.31% and a negative return on equity of 63.41%. The firm had revenue of $0.10 million during the quarter.
Shares of KalVista Pharmaceuticals (NASDAQ:KALV) traded down 0.12% during trading on Friday, reaching $8.00. 2,384 shares of the company traded hands. The stock’s market capitalization is $77.70 million. KalVista Pharmaceuticals has a 12 month low of $6.09 and a 12 month high of $10.65. The company has a 50-day moving average of $8.52 and a 200-day moving average of $7.88.
COPYRIGHT VIOLATION WARNING: “KalVista Pharmaceuticals, Inc. (KALV) Issues Quarterly Earnings Results, Beats Estimates By $0.08 EPS” was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/15/kalvista-pharmaceuticals-inc-kalv-issues-quarterly-earnings-results-beats-estimates-by-0-08-eps.html.
Several equities analysts recently issued reports on KALV shares. BTIG Research started coverage on shares of KalVista Pharmaceuticals in a report on Thursday, August 31st. They set a “buy” rating and a $18.00 price target for the company. ValuEngine raised shares of KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 2nd.
About KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.